Last reviewed · How we verify
Vasopressins
At a glance
| Generic name | Vasopressins |
|---|---|
| Also known as | vasopressin, Arginine vasopressin, Vasopressin inj, Argipressin |
| Sponsor | University Hospitals Cleveland Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial (PHASE2)
- Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
- Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair (PHASE2)
- Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressins CI brief — competitive landscape report
- Vasopressins updates RSS · CI watch RSS
- University Hospitals Cleveland Medical Center portfolio CI